BioCentury
ARTICLE | Translation in Brief

See-saw sweet spot

PPARγ antagonists could boost bone mass

July 30, 2015 7:00 AM UTC

Researchers at the Scripps Research Institute believe analogs of their recently published PPARγ antagonists could be a viable therapy for osteoporosis, particularly if the team can convince industry that the compounds don't carry the health risks of PPARγ agonists.

In a study published last month in Nature Communications,the authors reported the synthesis and structure of a set of compounds that inhibit the transcription factor, and as a result decrease adipogenesis and promote osteogenesis in vitro...